Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst

Key Points

• Axsome Therapeutics has experienced a downgrade in its Q3 2025 earnings per share estimate from ($0.82) to ($0.83) as per analyst M. Goodman from Leerink Partners.
• The consensus estimate for Axsome's full-year earnings for 2025 is projected at ($3.33) EPS, with 2026 earnings expected to turn positive at $0.30 EPS.
• Despite the downgrade, the stock maintains a consensus rating of "Buy" among analysts, with a price target average of $177.93.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.83) for the quarter, down from their prior forecast of ($0.82). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($3.33) EPS and FY2026 earnings at $0.30 EPS.

A number of other equities analysts also recently commented on the company. Needham & Company LLC restated a "buy" rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a report on Monday, August 4th. Morgan Stanley started coverage on Axsome Therapeutics in a report on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 price objective on the stock. Royal Bank Of Canada raised their target price on Axsome Therapeutics from $184.00 to $189.00 and gave the company an "outperform" rating in a report on Tuesday, August 5th. B. Riley started coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They set a "buy" rating and a $179.00 target price on the stock. Finally, Bank of America raised their target price on Axsome Therapeutics from $173.00 to $176.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $177.93.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $118.71 on Thursday. The stock's 50-day moving average is $116.04 and its 200-day moving average is $110.03. The company has a market cap of $5.92 billion, a price-to-earnings ratio of -23.41 and a beta of 0.52. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. Axsome Therapeutics has a 12 month low of $75.56 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.08. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.

Insiders Place Their Bets

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $118.84, for a total transaction of $1,518,062.16. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $859,094.36. The trade was a 63.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $115.96, for a total value of $1,159,600.00. The disclosure for this sale can be found here. Insiders have sold 243,332 shares of company stock valued at $28,824,746 over the last 90 days. 22.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. Assenagon Asset Management S.A. increased its holdings in Axsome Therapeutics by 16,852.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after purchasing an additional 623,717 shares during the last quarter. Norges Bank acquired a new position in shares of Axsome Therapeutics in the 2nd quarter worth approximately $48,889,000. Nuveen LLC acquired a new position in shares of Axsome Therapeutics in the 1st quarter worth approximately $48,185,000. Adage Capital Partners GP L.L.C. grew its position in shares of Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company's stock worth $46,662,000 after acquiring an additional 399,000 shares in the last quarter. Finally, Hood River Capital Management LLC acquired a new position in shares of Axsome Therapeutics in the 2nd quarter worth approximately $38,740,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.